Next Science

Next Science Debt/Market Cap

Delisted

The Debt to Market Capitalization Ratio of Next Science (NXS.AX) as of Nov 18, 2026 is 5.88 %. In the previous year, Debt to Market Capitalization Ratio was 2.27 % — a change of 159.17% (higher).

Debt/Market Cap

5.88 %

YoY

159.17%

Last updated:

Debt to Market Capitalization Ratio of Next Science is 2024 5.88 % . Debt to Market Capitalization Ratio of Next Science was 2023 2.27 % . It decreases by 159.17% higher compared to the previous year.

The Next Science Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2017
0.96 USD
Jan 1, 2018
16.66 USD
Jan 1, 2019
1.14 USD
Jan 1, 2020
0.68 USD
Jan 1, 2021
0.65 USD
Jan 1, 2022
2.88 USD
Jan 1, 2023
2.27 USD
Jan 1, 2024
5.88 USD
The Next Science Debt/Market Cap history
YEARDebt/Market CapYoY
5.88 %+159.17%
2.27 %-21.15%
2.88 %+342.03%
0.65 %-3.77%
0.68 %-40.56%
1.14 %-93.17%
16.66 %+1,634.40%
0.96 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Next Science Stock analysis

What does Next Science do? Next Science Ltd. generates revenue through the development and commercialization of its XBIO technology, which addresses bacterial biofilm-related infections in human health. The company's product portfolio includes XPERIENCE, a solution for preventing surgical site infections by rinsing away debris and microorganisms, and SurgX Sterile Antimicrobial Gel, designed to reduce surgical and post-surgical infections through sustained antibacterial action for up to five days. Blast X, an antimicrobial wound gel, targets bacterial infections in wounds. These products are sold to healthcare providers and medical facilities seeking effective solutions for bacterial biofilm eradication and infection prevention. The XBIO technology underpins all products, offering non-toxic efficacy against both biofilm and free-floating bacteria. XPERIENCE is used as a pre-surgical rinse, SurgX provides prolonged protection post-surgery, and Blast X treats existing wounds. Healthcare institutions, particularly hospitals and surgical centers, are the primary buyers, leveraging these products to enhance patient outcomes and reduce infection rates. Next Science Ltd. focuses on the healthcare sector, specifically targeting applications where bacterial biofilms pose significant risks. The company's products are positioned for use in surgical settings, wound care, and infection prevention protocols. By addressing critical needs in medical environments, the firm caters to healthcare providers who prioritize non-toxic, effective antimicrobial solutions for patient safety and operational efficiency. Next Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Next Science stock

Debt to Market Capitalization Ratio of Next Science is 5.88 % in 2024.

Debt to Market Capitalization Ratio of Next Science changed from 2.27 % to 5.88 %, representing a 159.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Next Science since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Next Science with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Next Science

All Key Metrics — Next Science